NJ-SPIRENT-COMM
9.2.2021 09:02:10 CET | Business Wire | Press release
Spirent Communications plc (LSE:SPT), the leading provider of test, assurance, and analytics solutions for next-generation devices and networks, today released its second annual 5G outlook report, based on analysis and takeaways from over 600 global 5G engagements in 2020. The “5G 2021: Market Drivers, Insights & Consideration” report provides insights from across the 5G eco-system on the current status of 5G, illustrating the accelerated timetables from service providers in upgrading to 5G standalone (SA) with the new 5G Core, and revealing how 5G is driving new initiatives and sector engagements. The report is available at www.spirent.com/assets/the-spirent-2021-5g-report .
“2020 was certainly a year to remember, not just because of the unprecedented challenges presented by COVID-19, but also because of the rapid development for the telecom industry,” said Spirent Head of 5G Strategy, Steve Douglas. “Telecom is keeping its sights firmly focused on 5G’s future, not in spite of the challenges of the pandemic, but because of them, and our latest report gives an unparalleled view of the current status of 5G and the trends we’re seeing for the year ahead, based on the investments, research, testing and innovation by the leading 5G players.”
The report draws on Spirent’s work with operators, network equipment manufacturers, government, military, and device makers across the globe. It provides an updated, behind-the-scenes view of what’s gone right so far, where challenges persist, and how what was learned during the year is impacting priorities for 2021 and beyond. Key findings from the report include:
- 5G SA core timetables accelerated rapidly: 5G activity surged in 2020 with accelerated timetables from service providers to deliver 5G SA core deployments, following non-standalone’s (NSAs) inability to really wow customers and deliver a solid new revenue proposition. Service Provider engagement increased nearly 50% as Service Assurance integration ramped up, and leading operators accelerated 5G standalone network strategies and new 5G core deployments.
- Because 5G is moving so fast, operators are turning to partners to deliver key elements : Through service contracts, elements that would previously have been delivered inhouse are now being delivered by trusted partners, as operators need to be able to move quickly to keep up with the complexity of 5G and the accelerated timetables.
- 5G is driving new initiatives and engagements: The year saw notable growth in engagements with government, military and academia around 5G experimentation and security initiatives, as governments explore new use cases. Other notable initiatives include Cloud hyperscalers exploring operator edge partnerships, Open RAN being explored in support of supply chain diversity initiatives, and multichannel video programming distributors (MVPDs) accelerating their plans for 5G.
- Automated Assurance and 5G are the new dynamic duo: Whether it was a core network buildout, lab certification, or new service delivered, 5G plus Automated Assurance were the dynamic duo that customers turned to as they sought to continue pushing forward with their 5G plans, with 80% of Spirent’s assurance business focused on 5G work.
- The trend of accelerated timetables is here to stay: While the pandemic has undoubtedly accelerated 5G timetables, it seems likely this accelerated trend is here to stay.
“In many ways, the pandemic has accelerated trends that we hadn’t anticipated gaining steam for at least another couple of years,” said Douglas, “whether fixed wireless access driven by working from home, or automation required to safely conduct field testing with limited personnel. While there were delays, by and large 5G powered ahead and remained in control of its destiny.”
“Spirent provides us with a real-world glimpse into 5G deployments today,” said Patrick Kelly, Founder and Principal Analyst at Appledore Research. “Spirent has a unique perspective in the 5G ecosystem as a leader in test and assurance solutions. The report provides insights into the current status of 5G and what’s coming next, particularly in 5G core, transport, network security, Open RAN progress, and the role of automated assurance.”
Spirent’s “5G 2021: Market Drivers, Insights & Consideration ” report offers a broad view of market-wide 5G challenges, opportunities and plans, and is available as a download at https://www.spirent.com/assets/the-spirent-2021-5g-report .
About Spirent
Spirent Communications plc. (LSE: SPT) is the leading global provider of automated test and assurance solutions for networks, cybersecurity, and positioning. The company provides innovative products, services and managed solutions that address the test, assurance and automation challenges of a new generation of technologies, including 5G, SD-WAN, cloud, autonomous vehicles and beyond. From the lab to the real world, Spirent helps companies deliver on their promise to their customers of a new generation of connected devices and technologies. For more information, please visit www.spirent.com and follow us on LinkedIn , Twitter and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005179/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom